Charles River Laboratories (CRL)
NYSE · Healthcare · Diagnostics & Research
Charles River Laboratories is a Healthcare company with a market capitalization of $12.97B.
5-Year Price History
Latest Annual Financials · FY ending December 31, 2025
Recent Quarterly Earnings (EPS)
| Quarter | Reported | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| Q1 2026 | May 7, 2026 | $2.06 | $1.95 | +5.6% |
| Q4 2025 | February 18, 2026 | $2.39 | $2.33 | +2.6% |
| Q3 2025 | November 5, 2025 | $2.43 | $2.32 | +4.7% |
| Q2 2025 | August 6, 2025 | $3.12 | $2.55 | +22.4% |
| Q1 2025 | May 7, 2025 | $2.34 | $2.07 | +13.0% |
| Q4 2024 | February 19, 2025 | $2.66 | $2.53 | +5.1% |
Short Interest
FINRA-reported short interest for semi-monthly settlement dates, published about nine business days after each settlement. Share counts are adjusted to the current split basis.
| Settlement | Shares Short | % of Shares Out | Days to Cover | Change |
|---|---|---|---|---|
| July 15, 2026 | 3,343,526 | 6.83% | 4.0 | -23.2% |
| June 30, 2026 | 4,354,792 | 8.90% | 4.3 | +20.5% |
| June 15, 2026 | 3,612,693 | 7.38% | 5.2 | -7.3% |
| May 29, 2026 | 3,897,904 | 7.96% | 3.6 | +7.3% |
| May 15, 2026 | 3,632,420 | 7.42% | 3.8 | +8.5% |
| April 30, 2026 | 3,349,211 | 6.81% | 4.5 | -28.2% |
| April 15, 2026 | 4,666,350 | 9.48% | 5.4 | +1.6% |
| March 31, 2026 | 4,594,794 | 9.34% | 5.3 | +22.3% |
Other Diagnostics & Research Stocks
Frequently Asked Questions
What is Charles River Laboratories's market cap?
As of August 13, 2026, Charles River Laboratories (CRL) has a market capitalization of $12.97B.
Does Charles River Laboratories pay a dividend?
Charles River Laboratories does not currently pay a dividend.
What sector is CRL in?
Charles River Laboratories is in the Healthcare sector, specifically the Diagnostics & Research industry.
What is Charles River Laboratories's short interest?
As of the July 15, 2026 FINRA settlement, 3,343,526 CRL shares were sold short, or 6.83% of shares outstanding. Days to cover: 4.0. FINRA publishes short interest twice a month, about nine business days after each settlement date.
What was Charles River Laboratories's revenue?
In its latest reported fiscal year (ending December 31, 2025), Charles River Laboratories reported revenue of $4.02B and net income of -$144.34M.
Ask your own questions about CRL
Try mrmarket.ai freeData as of August 13, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.